Takeda Pharmaceutical Company Ltd. / TiGenix NV

Complex perianal fistulas in Crohn's disease

Disease Overview

Complex perianal fistulas are debilitating tunnels that develop between the anal canal and surrounding skin in Crohn's disease patients, causing pain, drainage, recurrent infection, and risk of fecal incontinence. Standard care combines anti-TNF biologics with surgery, but durable closure of refractory fistulas remains a major unmet need.

Competitive Landscape

At deal time (February 2018), Cx601 (Alofisel) was the first and only allogeneic stem cell therapy targeting complex perianal fistulas, having received a positive CHMP opinion in late 2017 and EMA approval in March 2018. Standard of care relied on anti-TNF biologics — primarily infliximab (Remicade, J&J/Merck) and adalimumab (Humira, AbbVie) — combined with surgical setons, advancement flaps, or fistulotomy. Vedolizumab (Entyvio, Takeda's own) and ustekinumab (Stelara, J&J) were emerging IBD biologics with limited fistula-specific data. The Phase 3 ADMIRE-CD trial showed Alofisel achieved 50% combined remission vs 34% for control at 24 weeks, representing the first novel mechanism for refractory cases. The deal strengthened Takeda's GI franchise (anchored by Entyvio) with a differentiated cell therapy and US development upside via the planned ADMIRE-CD II registrational trial. The bull case unraveled in 2023 when ADMIRE-CD II failed its primary endpoint at week 24, and Takeda subsequently announced in 2024 that it would not pursue US approval and would discontinue Alofisel commercialization in most markets.